Rocuronium 0.3 mg·kg−1 (ED95) induces a normal peak effect but an altered time course of neuromuscular block in patients with Duchenne's muscular dystrophy

    loading  Checking for direct PDF access through Ovid


SummaryBackgroundIn patients with Duchenne's muscular dystrophy (DMD) recovery from neuromuscular block is delayed. It has been assumed that this is because of a higher potency of muscle relaxants in this patient cohort. We determined the peak effect, and the time course of action of rocuronium 0.3 mg·kg−1 (ED95) in DMD patients.MethodsTwenty-four patients (12 with DMD and 12 controls; aged 10–18 years) were studied. All patients were anesthetized with propofol and fentanyl/remifentanil. Neuromuscular transmission was monitored by acceleromyography. After induction all patients received a single dose of rocuronium 0.3 mg·kg−1. The complete time course of action as onset, peak effect and spontaneous recovery was recorded.ResultsThe onset time (s) to maximum block was significantly (P < 0.01) prolonged in DMD patients (median: 315; range: 120–465) compared with controls (195, 75–270). The peak effect (% twitch depression relative to baseline) was not different between the groups (DMD: 59–100; controls: 28–100). In the DMD group, recovery was significantly (P < 0.01) delayed compared with controls at all recorded time points. The clinical duration (min) was 40.3 (22–89) in the DMD group vs 9.8 (6–17) in the control group (P < 0.01).ConclusionsThe similar peak effect in both groups does not confirm the thesis of rocuronium having a higher potency in DMD patients. The documented very long recovery after the ED95 of rocuronium emphasizes the need for careful assessment of neuromuscular function in DMD patients.

    loading  Loading Related Articles